People | February 14, 2023
Sanofi announces change in R&D leadership
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Transformation to pure-play Innovative Medicines company nears completion
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Neural sleeve first algorithm-powered bionic garment designed to help those with mobility issues due to multiple sclerosis, stroke, cerebral palsy, and other conditions, regain functional movement in everyday activities
Nearly 1 million people are living with multiple sclerosis in the United States. Spasticity is a commonly reported symptom for MS, with an estimated prevalence of spasticity of 67%
The company will manufacture a cancer immunotherapy product from 2022
It is a novel oral NLRP3 inflammasome inhibitor
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Subscribe To Our Newsletter & Stay Updated
